Research study Program year 2025 Source: CMS Open Payments

Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment

Research payments

$5,853,841

8,075 payments

Through program year 2025, $5,853,841 in research payments was reported against Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment, across 8,075 payments.

Paid by (largest first): Roche Products Limited; Hoffmann-La Roche Limited; Genentech, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$764,372	2,221
2024	Research	$801,968	2,433
2023	Research	$818,423	2,438
2022	Research	$1,114,322	361
2021	Research	$1,364,240	363
2020	Research	$990,516	259

Breakdown

Who paid Research payments · program years 2020–2025

Roche Products Limited $5,850,954 8,072 payments
Hoffmann-La Roche Limited $2,700 2 payments
Genentech, Inc. $187 1 payment

Who received the money Research payments · program years 2020–2025

Massachusetts General Hospital Teaching hospital · MA $283,132 439 payments
Dragonfly Research LLC Organisation paid for research $199,480 333 payments
Meridian Clinical Research LLC Organisation paid for research $196,707 148 payments
Wright State University Organisation paid for research $178,333 256 payments
Riverside Regional Medical Center Teaching hospital · VA $168,479 263 payments
Riverhills Healthcare INC Organisation paid for research $163,978 305 payments
Thomas Jefferson University Organisation paid for research $159,615 330 payments
International Neurorehabilitation Institute Organisation paid for research $156,352 426 payments
Ochsner Clinic Foundation Teaching hospital · LA $136,152 220 payments
Neurology Center Of New England Pc Organisation paid for research $129,427 146 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

5 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.